BOSSI, ELISA

BOSSI, ELISA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 7 di 7 (tempo di esecuzione: 0.007 secondi).
Titolo Tipologia Data di pubblicazione Autori File
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 01 - Articolo su rivista 2023 Rindone, GiovanniAroldi, AndreaBossi, ElisaVerga, LuisaZambrotta, GiovanniTarantino, SaraPiazza, RoccoGambacorti-Passerini, Carlo +
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 01 - Articolo su rivista 2023 Aroldi, AMauri, MRamazzotti, DVilla, MMalighetti, FCrippa, VCocito, FBorella, CBossi, ESteidl, CScollo, CMologni, LPiazza, RGambacorti Passerini, C +
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 01 - Articolo su rivista 2023 Borella C.Bossi E.Ferrari M. B.Cotilli G.Gambacorti-Passerini C.Cairoli R.Puoti M. +
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 01 - Articolo su rivista 2022 Bossi, ElisaAroldi, AndreaBorin, Lorenza MariaVerga, LuisaFontana, DilettaCocito, FedericaManghisi, BeatriceRindone, GiovanniCavalca, FabrizioRipamonti, AlessiaAntolini, LauraPiazza, Rocco GiovanniGambacorti-Passerini, Carlo +
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 01 - Articolo su rivista 2020 Crespiatico, IlariaBossi, ElisaPiazza, RoccoMologni, LucaGambacorti‐Passerini, Carlo +
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 01 - Articolo su rivista 2020 Bossi E.Aroldi A.Steidl C.Verga L.Fontana D.Sharma G. G.Mologni L.Piazza R.Gambacorti Passerini C. +
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 02 - Intervento a convegno 2019 Bossi ESteidl CFontana DSharma GGMologni LPiazza RGGambacorti Passerini C +